One Size Rarely Fits All: The Hidden Flaws in How Your Prescription Dosage Was Chosen

When a physician writes a prescription, the dosage they select is rarely the result of a calculation tailored to your height, weight, liver function, or genetic profile. More often, it reflects a number derived from population-level clinical trial data—an average that was deemed effective and tolerable for a statistically representative group of participants. The problem, of course, is that you are not a statistical average. You are an individual, and the gap between what a standard dose does in a trial setting and what it does inside your specific body can be significant.

At TabOrderRx, we believe that informed patients are better equipped to have productive conversations with their healthcare providers. Understanding how dosage recommendations are established—and why they frequently fall short—is a critical piece of that puzzle.

How Drug Dosages Are Established in the First Place

Before a medication reaches pharmacy shelves, it undergoes a series of clinical trials designed to identify a therapeutic window: the range of doses that produce a desired effect without causing unacceptable harm. Phase I trials test safety and tolerability in small groups, often healthy volunteers. Phase II and III trials expand to larger populations to assess efficacy. The dosage that emerges from this process represents what worked best, on average, across those trial participants.

Historically, clinical trial populations have skewed toward younger, male, and otherwise healthy participants. Women, older adults, individuals with multiple chronic conditions, and people across the full spectrum of body compositions have been systematically underrepresented. The result is a pharmaceutical landscape where standard dosing was calibrated against a narrow demographic and then applied broadly—to everyone.

When a 130-pound elderly woman and a 240-pound middle-aged man receive the same milligram dose of a blood thinner or an antidepressant, the physiological reality of what that dose does in each body can be dramatically different. Yet identical prescriptions are written every day.

The Biological Variables That Standard Dosing Ignores

Several well-documented physiological factors influence how a medication behaves once it enters the body, and most of them are invisible to a prescriber relying solely on population-based guidelines.

Body composition and weight affect the volume of distribution—essentially, how widely a drug spreads throughout the body's tissues. Medications that are lipid-soluble behave differently in individuals with higher body fat percentages than in leaner patients.

Kidney and liver function determine how quickly a drug is metabolized and cleared. Patients with even mildly reduced kidney function may accumulate drug levels that would be considered toxic in someone with fully functional renal clearance. This is particularly relevant for older adults, in whom organ function naturally declines with age, often without obvious symptoms.

Age-related physiology introduces a range of variables beyond organ function alone. Changes in gastric motility, plasma protein levels, and total body water all influence how drugs are absorbed, distributed, and eliminated. Dosing guidelines for geriatric patients exist, but they are not always applied consistently in clinical practice.

Concurrent medications create interaction profiles that can either amplify or suppress a drug's effect. Enzyme inhibitors—substances that slow the metabolism of other drugs—can cause a standard dose to accumulate to dangerous levels. Enzyme inducers do the opposite, potentially rendering a therapeutic dose ineffective.

Pharmacogenomics: The Science That Could Change Everything

Perhaps the most consequential variable of all is one that cannot be observed, measured at a standard office visit, or inferred from a patient's appearance: genetic variation in drug-metabolizing enzymes.

Pharmacogenomics is the study of how an individual's genetic makeup influences their response to medications. Enzymes produced by genes in the cytochrome P450 family are responsible for metabolizing a large proportion of commonly prescribed drugs, including many antidepressants, antipsychotics, pain medications, and cardiovascular agents. Variations in these genes mean that some patients metabolize certain drugs far more rapidly than average—a classification known as ultrarapid metabolizers—while others process them far more slowly, earning the designation of poor metabolizers.

For an ultrarapid metabolizer prescribed a standard dose of a pain medication, the drug may be cleared so quickly that it provides little to no relief. For a poor metabolizer on the same dose, the drug may accumulate to levels that produce significant side effects or even toxicity. Neither outcome reflects a problem with the medication itself. Both reflect a mismatch between a population-derived dose and an individual's biology.

Pharmacogenomic testing is commercially available in the United States and is increasingly covered by insurance for specific clinical indications. Several major health systems have begun integrating genetic data into their electronic medical records to guide prescribing decisions. Despite this progress, routine pharmacogenomic testing remains far from standard practice in most outpatient settings.

When Patients Experience the Consequences

The practical consequences of dosing mismatches are not abstract. Patients who are underdosed may spend months cycling through medications, assuming a drug class simply does not work for them, when the underlying issue was never the drug itself—only the amount prescribed. Patients who are overdosed may attribute side effects to the condition being treated, or to aging, or to stress, never connecting their symptoms to the medication sitting in their medicine cabinet.

This dynamic is particularly pronounced in psychiatry, where response to antidepressants and mood stabilizers varies enormously between individuals, and in pain management, where under-treatment due to dosing inadequacy has real consequences for quality of life. It also appears in anticoagulation therapy, where the difference between a therapeutic and a harmful dose can be measured in millimeters on a brain scan.

What You Can Do Right Now

Advocating for appropriate dosing begins with asking questions that most patients never think to raise. If you have been on a medication for several weeks and are not experiencing the expected benefit, or if you are experiencing side effects that seem disproportionate to what your prescriber anticipated, dosing may be a relevant conversation.

Specifically, consider asking your provider:

• Whether your weight, age, or kidney and liver function have been factored into the dose you were prescribed.
• Whether pharmacogenomic testing is appropriate for the medications you are taking, particularly if you are managing a psychiatric condition, chronic pain, or a cardiovascular disorder.
• Whether any of your current medications are known to inhibit or induce the enzymes responsible for metabolizing your other prescriptions.

Your pharmacist is also a valuable resource in this conversation. Pharmacists are trained in drug interactions and pharmacokinetics, and a consultation—whether in person or through a service like TabOrderRx—can surface concerns that a busy prescriber may not have had time to address.

Personalized Medicine Is Not a Future Concept—It Is an Available Tool

The infrastructure for more individualized prescribing already exists. Pharmacogenomic tests, therapeutic drug monitoring, and renal dosing calculators are all in clinical use today. What lags behind is the systematic application of these tools at the point of prescribing.

Until personalized dosing becomes the default rather than the exception, patients who understand the limitations of standard dosing are better positioned to advocate for themselves. The goal is not to override clinical judgment—it is to ensure that clinical judgment is informed by the full picture of who you are as a patient, not merely who you resemble in a clinical trial conducted decades ago.

Your medication should work for your body. If it is not, the dose may be the first place worth examining.